Bausch Health Americas, Inc.
bauschhealth.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
212
Active
16
Phase 3
85
Total enrollment
78,058
Pipeline matrix
Showing 15 of 15 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Brodalumab | — | — | — | 6 | |||
| IDP-122 Lotion | — | — | — | 4 | |||
| bupropion hydrobromide | — | — | — | — | — | 1 | |
| Rifaximin 200 mg | — | — | — | — | — | 1 | |
| High dose budesonide rectal foam | — | — | — | — | — | 1 | |
| Low dose budesonide rectal foam | — | — | — | — | — | 1 | |
| Low Dose Budesonide | — | — | — | — | — | 1 | |
| High Dose Budesonide | — | — | — | — | — | 1 | |
| CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%. | — | — | — | — | — | 1 | |
| Rifaximin SSD | — | — | — | — | — | 2 | |
| Larsucosterol | — | — | — | — | — | 1 | |
| clindamycin phosphate, adapalene and benzoyl peroxide | — | — | — | — | — | 1 | |
| Matched cohort | — | — | — | — | — | 1 | |
| Comparator Drug | — | — | — | — | — | 1 | |
| Pimecrolimus | — | — | — | — | — | 1 |
Next readouts
- 2025-02-05
- 2025-09
- 2026-01
- 2026-05
- 2026-08
- 2026-12
- 2027-04-20
- 2027-11
- 2027-12
- 2027-12
Top conditions
- Acne Vulgaris21
- Psoriasis16
- Ulcerative Colitis14
- Constipation9
- Plaque Psoriasis7
- Chronic Idiopathic Constipation7
- Acne6
- Healthy6
Frequently asked questions about Bausch Health Americas, Inc.
- How many clinical trials does Bausch Health Americas, Inc. have on ClinicalTrials.gov?
- Bausch Health Americas, Inc. is listed as the lead sponsor on 212 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Bausch Health Americas, Inc.'s trials are in Phase 3?
- 85 of Bausch Health Americas, Inc.'s trials are in Phase 3, spread across 15 active drug programs.
- What therapeutic areas does Bausch Health Americas, Inc. focus on?
- Bausch Health Americas, Inc.'s most-studied conditions on ClinicalTrials.gov are Acne Vulgaris, Psoriasis, Ulcerative Colitis, Constipation, Plaque Psoriasis.
- When are Bausch Health Americas, Inc.'s next clinical trial readouts?
- Bausch Health Americas, Inc. has 10 upcoming primary-completion readouts tracked here; the soonest is “Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity”, expected around 2025-02-05.